CD BioSciences Announces Cytoskeleton-Targeted Tumor Marker Development Service for Cancer Diagnosis
CD BioSciences has announced its cytoskeleton-based tumor marker development service for cancer diagnosis.
CD BioSciences, a prominent biotech company, has recently unveiled its latest and innovative service on tumor marker development. This groundbreaking service can be utilized for preclinical tests to determine the tumor type and predict disease progression.
...